The historical rank and industry rank for Dynavax Technologies's Gross Margin % or its related term are showing as below:
DVAX'
s Gross Margin % Range Over the Past 10 Years
Min: -265.14 Med: 62.12 Max: 82.17
Current: 82.17
During the past 13 years, the highestGross Margin % of Dynavax Technologies was 82.17%. The lowest was -265.14%. And the median was 62.12%.
DVAX's Gross Margin % is ranked better than 93.61% of 955
companies
in the Drug Manufacturers industry
Industry Median: 47.59
vs DVAX: 82.17
Dynavax Technologies had a gross margin of 81.38% for the quarter that ended in Dec. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Dynavax Technologies was 10.20% per year.
Dynavax Technologies Gross Margin % Historical Data
The historical data trend for Dynavax Technologies's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dynavax Technologies's Gross Margin %
For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynavax Technologies's Gross Margin % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Dynavax Technologies's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Dynavax Technologies had a gross margin of 81.38% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Dynavax Technologies Gross Margin % Related Terms
Thank you for viewing the detailed overview of Dynavax Technologies's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DVAX has been successfully added to your 